Midpoint Transverse Process to Pleura BlockNCT07732556
Midpoint Transverse Process to Pleura (MTP) Block vs Erector Spinae Plane (ESP) Block for Acute Herpes Zoster (HZ) Pain
A study testing Midpoint transverse process to pleura block and Erector spinae plane block in people with Midpoint Transverse Process to Pleura Block and Erector Spinae Plane Block, run by Tanta University at 1 site in Egypt.
Trial summary
The aim of this study is to compare the analgesic efficacy and safety of ultrasound-guided midpoint transverse process block versus ultrasound-guided erector spinae plane block in patients suffering from thoracic herpes zoster pain. Read more about this study
- Who is it for?
- Ages 21 to 60 years
- Conditions the study is for
- Midpoint Transverse Process to Pleura Block, Erector Spinae Plane Block, Acute Herpes Zoster
- What is being tested?
- Midpoint transverse process to pleura block and Erector spinae plane block
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jul 2026to 1 Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Age 21-60 years.
- Both sexes.
- American Society of Anesthesiologists (ASA) physical status I-II.
- Acute thoracic herpes zoster within 30 days of rash onset.
- Moderate to severe pain [numeric rating scale (NRS)≥4].
Who cannot join
- Refusal to participate.
- Coagulopathy or anticoagulant therapy.
- Infection at puncture site.
- Allergy to study drugs.
- Severe psychiatric illness or inability to assess pain.
- Previous thoracic surgery deformity.
Show all 10Show fewer
- Uncontrolled Diabetic patient.
- Chronic diseases as renal, hepatic, malignancy.
- Patients with chronic disease need analgesia.
- Patients are coming for more than 3 months (after healing of rash).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Tanta University
Tanta, El-Gharbia, 31527
Mohamed A Kazamel, MBBCH, 00201205997183, mohamed198330_pg@med.tanta.edu.eg
About this study
Official title: Comparison Between Midpoint Transverse Process to Pleura (MTP) Block vs Erector Spinae Plane (ESP) Block for Acute Herpes Zoster (HZ) Pain
The aim of this study is to compare the analgesic efficacy and safety of ultrasound-guided midpoint transverse process block versus ultrasound-guided erector spinae plane block in patients suffering from thoracic herpes zoster pain.
Read the detailed description
Herpes zoster is caused by reactivation of latent varicella-zoster virus in dorsal root or cranial nerve ganglia and commonly presents with unilateral dermatomal rash associated with severe neuropathic pain.
The erector spinae plane block is an ultrasound-guided interfascial plane block in which local anesthetic is deposited deep to the erector spinae muscle adjacent to the transverse process, allowing multidermatomal spread and thoracic analgesia. Recent studies support its efficacy in herpes zoster pain management.
The midpoint transverse process to pleura block is a paravertebral-by-proxy technique where local anesthetic is injected midway between the posterior border of the transverse process and pleura. It may provide thoracic segmental analgesia with lower pleural puncture risk and easier sonoanatomy.
- Conditions
- Midpoint Transverse Process to Pleura Block, Erector Spinae Plane Block, Acute Herpes Zoster, Pain
- Being tested
- Midpoint transverse process to pleura block, Erector spinae plane block
- Medical subject headings
- Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Midpoint transverse process to pleura blockOther
Patients will receive ultrasound-guided midpoint transverse process to pleura block using 10 mL 0.25% bupivacaine + 40 mg methylprednisolone.
Erector spinae plane blockOther
Patients will receive ultrasound -guided erector spinae plane block using 10 mL 0.25% bupivacaine + 40 mg methylprednisolone.
| Study group | Role | What they receive |
|---|---|---|
| Group MTP | Other | Patients will receive ultrasound-guided midpoint transverse process to pleura block using 10 mL 0.25% bupivacaine + 40 mg methylprednisolone. Receives: Other: Midpoint transverse process to pleura block |
| Group ESP | Other | Patients will receive ultrasound -guided erector spinae plane block using 10 mL 0.25% bupivacaine + 40 mg methylprednisolone. Receives: Other: Erector spinae plane block |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of post-herpatic neuralgia
Incidence of post-herpatic neuralgia will be recorded after 12 weeks of block
Measured: After 12 weeks of block
Secondary outcomes (9)
Blood pressure
Blood pressure will be recoded at time of block and following up at first 24 hours.
Measured: 24 hours postoperatively
Heart rate
Heart rate will be recoded at time of block and following up at first 24 hours.
Measured: 24 hours postoperatively
Oxygen saturation
Oxygen saturation will be recoded at time of block and following up at first 24 hours.
Measured: 24 hours postoperatively
Time to first rescue analgesia
Time to first rescue analgesia will be recorded from the end of surgery till first dose of Acetaminophen administrated.
Measured: 24 hours postoperatively
Total rescue analgesics consumption
Acetaminophen was offered on request as a rescue analgesic at a dosage of 1,000 mg. A maximum daily dosage of 4,000 mg will be permitted for people with Numerical Rating Scale (NRS)≥ 4.
Measured: 24 hours postoperatively
Degree of pain
Pain intensity will be assessed using the Numerical Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst imaginable pain. NRS will be recorded at 30 minutes, 2 hours, 6 hours, 12 hours, 24 hours, after first 24 hours, 1 week, 2 weeks, 4 weeks, 8 weeks, and 12 weeks postoperatively
Measured: 12 weeks postoperatively
Total anti-convulsant drugs
Total anti-convulsant drugs will be recorded at at 24 hours, 1 week, 2 weeks, 4 weeks, 8 weeks and 12 weeks postoperatively
Measured: 12 weeks postoperatively
Assessment of sleep quality
The Pittsburgh Sleep Quality Index (PSQI) is a 19-item self-report questionnaire will be used to assess the sleep quality.
It evaluates seven clinical components: subjective sleep quality, sleep latency, duration, efficiency, disturbances, medication use, and daytime dysfunction.
Each of the 7 components is scored on a scale from 0 to 3, where 0 indicates no difficulty and 3 indicates severe difficulty.
Subjective Sleep Quality (Self-rated overall quality) Sleep Latency (Time it takes to fall asleep) Sleep Duration (Total hours slept per night) Habitual Sleep Efficiency (Percentage of time in bed spent asleep) Sleep Disturbances (Nighttime awakenings, breathing issues, etc.) Use of Sleeping Medication (Frequency of sleep aids) Daytime Dysfunction (Trouble staying awake or lack of enthusiasm during the day)
≤ 5: Indicates good sleep quality. > 5: Indicates poor sleep quality.
Measured: 12 weeks postoperatively
Incidence of complications
Incidence of complications such as pneumothorax, local anesthetic systemic toxicity, epidural spread, pleural puncture, and block failure will be recorded.
Measured: 24 hours postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jul 2026
- Study start1 Jul 2026
- Primary completion1 Jun 2027 (estimated)
- Study completion1 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Midpoint Transverse Process to Pleura BlockStudies of the same condition, open and under way.
- More trials run by Tanta UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tanta University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Ahmed Kazamel, Tanta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07732556
- Sponsor's protocol ID
- 36265MS150/6/26
- Status last verified
- Jul 2026
- First submitted
- 23 Jul 2026
- Last updated
- 29 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 29 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison Between Midpoint Transverse Process to Pleura (MTP) Block vs Erector Spinae Plane (ESP) Block for Acute Herpes Zoster (HZ) Pain
- ClinicalTrials.gov ID
- NCT07732556
- Acronym / sponsor ID
- 36265MS150/6/26
- Conditions
- Midpoint Transverse Process to Pleura Block, Erector Spinae Plane Block, Acute Herpes Zoster, Pain
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Tanta UniversityUniversity, hospital or other
- Study start
- 1 Jul 2026 (actual)
- Primary completion
- 1 Jun 2027 (estimated)
- Study completion
- 1 Jun 2027 (estimated)
- First posted
- 29 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to compare the analgesic efficacy and safety of ultrasound-guided midpoint transverse process block versus ultrasound-guided erector spinae plane block in patients suffering from thoracic herpes zoster pain.
Detailed description
Herpes zoster is caused by reactivation of latent varicella-zoster virus in dorsal root or cranial nerve ganglia and commonly presents with unilateral dermatomal rash associated with severe neuropathic pain.
The erector spinae plane block is an ultrasound-guided interfascial plane block in which local anesthetic is deposited deep to the erector spinae muscle adjacent to the transverse process, allowing multidermatomal spread and thoracic analgesia. Recent studies support its efficacy in herpes zoster pain management.
The midpoint transverse process to pleura block is a paravertebral-by-proxy technique where local anesthetic is injected midway between the posterior border of the transverse process and pleura. It may provide thoracic segmental analgesia with lower pleural puncture risk and easier sonoanatomy.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group MTP | Other | Other: Midpoint transverse process to pleura blockPatients will receive ultrasound-guided midpoint transverse process to pleura block using 10 mL 0.25% bupivacaine + 40 mg methylprednisolone. |
| Group ESP | Other | Other: Erector spinae plane blockPatients will receive ultrasound -guided erector spinae plane block using 10 mL 0.25% bupivacaine + 40 mg methylprednisolone. |
Who may qualify
- Ages
- 21 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Age 21-60 years.
- Both sexes.
- American Society of Anesthesiologists (ASA) physical status I-II.
- Acute thoracic herpes zoster within 30 days of rash onset.
- Moderate to severe pain [numeric rating scale (NRS)≥4].
Key exclusion criteria (10 listed)
- Refusal to participate.
- Coagulopathy or anticoagulant therapy.
- Infection at puncture site.
- Allergy to study drugs.
- Severe psychiatric illness or inability to assess pain.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Midpoint transverse process to pleura blockPatients will receive ultrasound-guided midpoint transverse process to pleura block using 10 mL 0.25% bupivacaine + 40 mg methylprednisolone. | Other | Group MTP |
| Erector spinae plane blockPatients will receive ultrasound -guided erector spinae plane block using 10 mL 0.25% bupivacaine + 40 mg methylprednisolone. | Other | Group ESP |
Primary outcome
Incidence of post-herpatic neuralgia
Time frame: After 12 weeks of block
Incidence of post-herpatic neuralgia will be recorded after 12 weeks of block
9 secondary outcomes
Blood pressure
Time frame: 24 hours postoperatively
Heart rate
Time frame: 24 hours postoperatively
Oxygen saturation
Time frame: 24 hours postoperatively
Time to first rescue analgesia
Time frame: 24 hours postoperatively
Total rescue analgesics consumption
Time frame: 24 hours postoperatively
Degree of pain
Time frame: 12 weeks postoperatively
Total anti-convulsant drugs
Time frame: 12 weeks postoperatively
Assessment of sleep quality
Time frame: 12 weeks postoperatively
Incidence of complications
Time frame: 24 hours postoperatively
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jul 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Midpoint Transverse Process to Pleura Block
Not yet recruiting
Ultrasound-Guided Midpoint Transverse Process to Pleura Block Versus Erector Spinae Plane Block for Postoperative Analgesia in Patients Undergoing Open Renal Surgery :A Randomized Comparative Study.
Postoperative Analgesia in Patients Undergoing Open Renal Surgery
Recruiting
Comparison of the Effectiveness of Midpoint Transverse Process to Pleura (MTP) Block and Erector Spinae Plane (ESP) Block in Video-Assisted Thoracoscopic Surgery (VATS) at RS Ngoerah
Pain, Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Midpoint transverse process to pleura block and Erector spinae plane block in people with Midpoint Transverse Process to Pleura Block and Erector Spinae Plane Block, run by Tanta University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mohamed A Kazamel, MBBCH (00201205997183, mohamed198330_pg@med.tanta.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of post-herpatic neuralgia (time frame: After 12 weeks of block). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2026.